The clinical spectrum of non-dementia cognitive impairment: Subjective mild-to-moderate disorders

Nevrologiâ, Nejropsihiatriâ, Psihosomatika. 2016;7(4):83-91 DOI 10.14412/2074-2711-2015-4-83-91

 

Journal Homepage

Journal Title: Nevrologiâ, Nejropsihiatriâ, Psihosomatika

ISSN: 2074-2711 (Print); 2310-1342 (Online)

Publisher: IMA-PRESS LLC

LCC Subject Category: Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry: Neurology. Diseases of the nervous system

Country of publisher: Russian Federation

Language of fulltext: Russian

Full-text formats available: PDF

 

AUTHORS

V. V. Zakharov (I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia)
N. V. Vakhnina (I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia)
D. O. Gromova (I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia)
N. E. Ter-Ovanesova (I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia)
A. V. Tarapovskaya (I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia)

EDITORIAL INFORMATION

Double blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 6 weeks

 

Abstract | Full Text

The important task of nevrology is to improve the diagnosis of chronic progressive degenerative and vascular brain diseases – to detect them at the earliest stages. The paper presents current views on the non-dementia stages of brain diseases: moderate, mild, and subjective cognitive impairments. It sets forth data on their prevalence and clinical features and types, as well as international diagnostic criteria. There is evidence for the expediency of the earliest neuroprotective therapy to prevent dementia. A methodology for neuroprotective therapy is discussed; the available data on the long-term effect of intermittent treatment cycles with the vasotropic and neurometabolic drug tanakan are given.